Alembic Pharma Q2 net surges 81% to ₹335 crore
The Hindu

“U.S. business was driven by strong volume growth and new launches. In U.S.
Branded, we are encouraged by the traction building across our existing
portfolio,” said
The Hindu

“U.S. business was driven by strong volume growth and new launches. In U.S.
Branded, we are encouraged by the traction building across our existing
portfolio,” said
Several outlets reported this. AI can compare where they agree and differ.
EconomyThe Hindu
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
MarketsCNBC-TV18
Jubilant Pharmova reported a 74.1% year-on-year decline in Q2 FY27 consolidated net profit to ₹31.2 crore, even as revenue from operations grew 20.5% to ₹2,370 crore. EBITDA fell 29.3% to ₹241 crore, with the margin narrowing to 10.2% from 17.4%.
EconomyNDTV
The company had posted a net loss of Rs 52.8 crore in the year-ago period.
MarketsEconomic Times
Gland Pharma shares rose nearly 4% after the company reported a 58% increase in Q2 net profit and a 23% rise in revenue.
MarketsThe Hindu
Thermal and hydro operations led growth, with earnings surging 158.3% to ₹1,066.66 crore in Q2.
EconomyThe Hindu
Revenue crosses ₹1,500 crore despite higher input and logistics costs driven by West Asia tensions, expect cost pressures to persist, says CMD Chigurupati
EconomyLiveMint
The company reported an almost 59% jump in consolidated net profit to ₹7,532 crore in Q2, but a 39% rise in input costs during the quarter threatens to squeeze near-term margins.